References
- Cavaliere M, Bisogno A, Scarpa A, D’Urso A, Marra P, Colacurcio V, et al. Biomarkers of laryngeal squamous cell carcinoma: a review. Ann Diagn Pathol 2021; 54: 151787. doi: 10.1016/j.anndiagpath.2021.151787
- Kim DH, Kim SW, Han JS, Kim GJ, Basurrah MA, Hwang SH. The prognostic utilities of various risk factors for laryngeal squamous cell carcinoma: a systematic review and meta-analysis. Medicina (Kaunas) 2023; 59: 497. doi: 10.3390/medicina59030497
- Fang Q, Xu P, Cao F, Wu D, Liu X. PD-1 Inhibitors combined with paclitaxel (Albumin-bound) and cisplatin for larynx preservation in locally advanced laryngeal and hypopharyngeal squamous cell carcinoma: a retrospective study. Cancer Immunol Immunother 2023; 72: 4161-8. doi: 10.1007/s00262-023-03550-z
- Khera N, Rajkumar AS, Abdulkader MAK, Liu Z, Ma H, Waseem A, et al. Identification of multidrug chemoresistant genes in head and neck squamous cell carcinoma cells. Mol Cancer 2023; 22: 146. doi: 10.1186/s12943-023-01846-3
- Liu Q, Niu X, Li Y, Zhang JR, Zhu SJ, Yang QY, et al. Role of the mucin-like glycoprotein FCGBP in mucosal immunity and cancer. Front Immunol 2022; 13: 863317. doi: 10.3389/fimmu.2022.863317
- Yan T, Tian D, Chen J, Tan Y, Cheng Y, Ye L, et al. FCGBP Is a prognostic biomarker and associated with immune infiltration in glioma. Front Oncol 2021; 11: 769033. doi: 10.3389/fonc.2021.769033
- Shen T, Zhang J, Wang Y, Liu B. FCGBP is a promising prognostic biomarker and correlates with immunotherapy efficacy in oral squamous cell carcinoma. J Immunol Res 2022; 2022: 8443392. doi: 10.1155/2022/8443392
- Zeng L, Zeng J, He J, Li Y, Li C, Lin Z, et al. FCGBP functions as a tumor suppressor gene in head and neck squamous cell carcinoma. Discov Oncol 2024; 15: 704. doi: 10.1007/s12672-024-01607-8
- Wang Y, Liu Y, Liu H, Zhang Q, Song H, Tang J, et al. FcGBP was upregulated by HPV infection and correlated to longer survival time of HNSCC patients. Oncotarget 2017; 8: 86503-14. doi: 10.18632/oncotarget.21220
- Ding Q, Lin F, Huang Z, Li Y, Cai S, Chen X, et al. Non-coding RNA-related FCGBP downregulation in head and neck squamous cell carcinoma: a novel biomarker for predicting paclitaxel resistance and immunosuppressive microenvironment. Sci Rep 2024; 14: 4426. doi: 10.1038/s41598-024-55210-6
- Su YT, Chen CH, Kang JW, Kuo HY, Yang CC, Tian YF, et al. Predictive value of FCGBP expression for treatment response and survival in rectal cancer patients undergoing chemoradiotherapy. Aging (Albany NY) 2024; 16: 7889-901. doi: 10.18632/aging.205791
- Ma X, Suo Z, Ma X, Zhan C, Luo G, Song J. Cinobufagin inhibits tumor progression and reduces doxorubicin resistance by enhancing FOXO1-mediated transcription of FCGBP in osteosarcoma. J Ethnopharmacol 2022; 296: 115433. doi: 10.1016/j.jep.2022.115433
- Gao W, Guo H, Niu M, Zheng X, Zhang Y, Xue X, et al. circPARD3 drives malignant progression and chemoresistance of laryngeal squamous cell carcinoma by inhibiting autophagy through the PRKCI-Akt-mTOR pathway. Mol Cancer 2020; 19: 166. doi: 10.1186/s12943-020-01279-2
- Lin XJ, Liu H, Li P, Wang HF, Yang AK, Di JM, et al. miR-936 suppresses cell proliferation, invasion, and drug resistance of laryngeal squamous cell carcinoma and targets GPR78. Front Oncol 2020; 10: 60. doi: 10.3389/fonc.2020.00060
- Jiang T, Sun Z, Dong K, Pu Q, Gao H, Lv Y, et al. PIGR predicts good clinical outcomes and plays a tumor suppressor role in the development of breast cancer. Front Oncol 2025; 15: 1439120. doi: 10.3389/fonc.2025.1439120
- Borzou A, Sadygov RG. A novel estimator of the interaction matrix in Graphical Gaussian Model of omics data using the entropy of non-equilibrium systems. Bioinformatics 2021; 37: 837-44. doi: 10.1093/bioinformatics/btaa894
- Park J, Yun HS, Lee KH, Lee KT, Lee JK, Lee SY. Discovery and validation of biomarkers that distinguish mucinous and nonmucinous pancreatic cysts. Cancer Res 2015; 75: 3227-35. doi: 10.1158/0008-5472.CAN-14-2896
- Erdogan F, Radu TB, Orlova A, Qadree AK, de Araujo ED, Israelian J, et al. JAK-STAT core cancer pathway: An integrative cancer interactome analysis. J Cell Mol Med 2022; 26: 2049-62. doi: 10.1111/jcmm.17228
- Routila J, Qiao X, Weltner J, Rantala JK, Carpen T, Hagstrom J, et al. Cisplatin overcomes radiotherapy resistance in OCT4-expressing head and neck squamous cell carcinoma. Oral Oncol 2022; 127: 105772. doi: 10.1016/j.oraloncology.2022.105772
- Xiong L, Wen Y, Miao X, Yang Z. NT5E and FcGBP as key regulators of TGF-1-induced epithelial-mesenchymal transition (EMT) are associated with tumor progression and survival of patients with gallbladder cancer. Cell Tissue Res 2014; 355: 365-74. doi: 10.1007/s00441-013-1752-1
- Zhuang Q, Shen A, Liu L, Wu M, Shen Z, Liu H, et al. Prognostic and immunological roles of Fc fragment of IgG binding protein in colorectal cancer. Oncol Lett 2021; 22: 526. doi: 10.3892/ol.2021.12787
- Wang J, Gong Z, Liu J, Wang W, Liu K, Yang Y, et al. Fc fragment of IgG binding protein suppresses tumor growth by stabilizing wild type P53 in colorectal cancer cells. BMC Cancer 2025; 25: 507. doi: 10.1186/s12885-025-13873-y
- Gentilin E. New advancements in cisplatin-based treatments. Int J Mol Sci 2023; 24: 5920. doi: 10.3390/ijms24065920
- Asanprakit W, Lobo DN, Eremin O, Bennett AJ. Expression of polymeric immunoglobulin receptor (PIGR) and the effect of PIGR overexpression on breast cancer cells. Sci Rep 2023; 13: 16606. doi: 10.1038/s41598-023-43946-6
- Arumugam P, Bhattacharya S, Chin-Aleong J, Capasso M, Kocher HM. Expression of polymeric immunoglobulin receptor and stromal activity in pancreatic ductal adenocarcinoma. Pancreatology 2017; 17: 295-302. doi: 10.1016/j.pan.2017.01.013
- Li Y, Zhu L, Yao H, Zhang Y, Kong X, Chen L, et al. Association of inflammation-related gene polymorphisms with susceptibility and radiotherapy sensitivity in head and neck squamous cell carcinoma patients in northeast China. Front Oncol 2021; 11: 651632. doi: 10.3389/fonc.2021.651632
- Xue C, Yao Q, Gu X, Shi Q, Yuan X, Chu Q, et al. Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer. Signal Transduct Target Ther 2023; 8: 204. doi: 10.1038/s41392-023-01468-7
- Liu Q, Zhang J, Zhang F, Zhang W, Gong L. [IgG Fc binding protein (FCGBP) as a prognostic marker of low-grade glioma and its correlation analysis with immune infiltration]. [Chinese]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2023; 39: 686-92. PMID: 37515334